Does Dr. SAMI ABDUL JAWAD have financial conflicts of interest?

Dr. SAMI ABDUL JAWAD (M.D.) has received a total of $118,715 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $118,715 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. SAMI ABDUL JAWAD?

According to CMS Open Payments data, Dr. SAMI ABDUL JAWAD received funding from GLAXOSMITHKLINE ($94,032), ASTRAZENECA PHARMACEUTICALS ($22,797), and PULMONX CORPORATION ($1,235).

Does Dr. SAMI ABDUL JAWAD receive research grants or speaking fees?

Dr. SAMI ABDUL JAWAD has received $118,715 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. SAMI ABDUL JAWAD

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Critical Care Medicine

Practice Location: FALLS CHURCH, VA 22042

NPI Number: 1487930905

LIFETIME INDUSTRY VALUE

$118,715

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. ABDUL JAWAD is a verified Internal Medicine, Critical Care Medicine practitioner based in FALLS CHURCH, VA.

Between 2021 and 2025, Dr. ABDUL JAWAD had an overall industry promotional and research financial footprint of $118,715 as recorded in the federal CMS Open Payments database.

$118,715 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ABDUL JAWAD's primary funding source is GLAXOSMITHKLINE, which accounts for $94,032 (representing 79.2% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GLAXOSMITHKLINE

Rank 1

$94,032

79.2%

ASTRAZENECA PHARMACEUTICALS

Rank 2

$22,797

19.2%

PULMONX CORPORATION

Rank 3

$1,235

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.